| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11129812 | ORASIS PHARMS | Ophthalmic pharmaceutical compositions and uses relating thereto |
Aug, 2037
(13 years from now) | |
| US10639297 | ORASIS PHARMS | Ophthalmic pharmaceutical compositions and uses relating thereto |
Aug, 2037
(13 years from now) | |
| US9867810 | ORASIS PHARMS | Ophthalmic pharmaceutical compositions and uses relating thereto |
Aug, 2037
(13 years from now) | |
Qlosi is owned by Orasis Pharms.
Qlosi contains Pilocarpine Hydrochloride.
Qlosi has a total of 3 drug patents out of which 0 drug patents have expired.
Qlosi was authorised for market use on 17 October, 2023.
Qlosi is available in solution;ophthalmic dosage forms.
Qlosi can be used as treatment of presbyopia.
The generics of Qlosi are possible to be released after 18 August, 2037.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 17, 2026 |
Drugs and Companies using PILOCARPINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 October, 2023
Treatment: Treatment of presbyopia
Dosage: SOLUTION;OPHTHALMIC
More Information on Dosage
QLOSI family patents
